Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent

Minocha, Prashant K.; Better, Donna; Singh, Rakesh K.; Hoque, Tasneem

doi:10.1016/j.jpeds.2021.06.035

Cited by 63 publications

(52 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After reviewing individual abstracts and full texts of the articles, we identified 20 studies (12 case reports and 8 case series) that met the inclusion criteria for this systematic review. 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 In addition, we carried out an additional search in the same databases on September 10, 2021, and added one case series and three case reports. 30 , 31 , 32 , 33 The search terms used are described in detail in Table S2 .…”

Section: Methodsmentioning

confidence: 99%

Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID‐19 vaccine

Woo

Kim

Yon

et al. 2021

Journal of Medical Virology

View full text Add to dashboard Cite

To analyze the clinical presentation and outcomes of myocarditis after administration of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccine. Nine case series and 15 case reports (74 patients) of myocarditis after administration of the BNT162b2 or mRNA-1273 vaccine were reviewed from PubMed, Scopus, Embase, and Web of Science. We analyzed clinical manifestations, diagnostic findings, and outcomes. In addition, we performed a pooled analysis and investigated risk factors leading to admission to the intensive care unit and recovery with conservative care. Most patients were male (94.6%), and the median age (range) was 17.6 (14-70) years. Patients who received the BNT162b2 (n = 58, 78.4%) vaccine presented fewer systemic symptoms and left ventricular dysfunction than mRNA-1273 recipients. Although patients under 20 years experienced more fever and myalgia, they had better ejection fraction and less prominent myocardial inflammation in magnetic resonance imaging than older patients. The clinical course of all patients was favorable without mortality, and onethird of patients resolved with conservative care alone. Risk factor analyses revealed that patients with gastrointestinal symptoms required intensive care

show abstract

Section: Methodsmentioning

confidence: 99%

Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID‐19 vaccine

Woo

Kim

Yon

et al. 2021

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…There is an increasing number of cases of myocarditis and pericarditis following vaccination with mRNA COVID-19. Most cases occur in adolescent boys, usually within a few days after vaccination with COVID-19 and after the second dose ( Salah & Mehta, 2021 Oct 15 , Minocha et al, 2021 ). In Israel, 110 cases of myocarditis were identified after administration of two doses of the Pfizer-BioNTech vaccine and 90% of the cases were in males ( Vogel & Couzin-Frankel, 2021 ).…”

Section: Discusionmentioning

confidence: 99%

“…All marketed vaccines have been proven to provide benefits that outweigh the potential associated risks among different age groups ( Haas et al, 2021 May 15 , Lopez Bernal et al, 2021 May 13 ). Some studies have reported cases of myocarditis in association with the different vaccines, mostly mild cases in young males after administration of the second dose of mRNA vaccines (Pfizer-BioNTech® and Moderna) ( Salah & Mehta, 2021 Oct 15 , Minocha et al, 2021 ). However, information on the characteristics and debut of COVID-19 vaccine-associated myocarditis is very limited.…”

Section: Introductionmentioning

confidence: 99%

Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review

Brage

Ruíz

Martín

et al. 2022

Current Problems in Cancer: Case Reports

View full text Add to dashboard Cite

“…All other publication types and articles published in languages other than English were excluded. Twenty-five unique manuscripts which reported post-mRNA vaccination myocarditis were identified [ 1 , 6 - 29 ]. Reference search resulted in the identification of two more articles [ 30 , 31 ].…”

Section: Reviewmentioning

confidence: 99%

Clinical Presentation and Outcomes of Myocarditis Post mRNA Vaccination: A Meta-Analysis and Systematic Review

Matta¹,

Kunadharaju²,

Osman³

et al. 2021

Cureus

View full text Add to dashboard Cite

Background: Myocarditis is being increasingly reported as a potential complication of both Pfizer-BioNTech and Moderna vaccines for COVID-19. One thousand five hundred and twenty-two cases were reported as of September 02, 2021, as per CDC’s (Centers for Disease Control) vaccine adverse event reporting system. Most of the published data is available in the form of case reports and series. There is a need to compile the demographic data, clinical features, and outcomes in these patients. Methods: A systematic search was conducted in PubMed, Embase, Web of science, and google scholar for published literature between January 01, 2020, and July 17, 2021. Individual data of 69 patients were pooled from 25 qualifying case reports and case series. Results: The median age of onset was 21 years. 92.7% of the patients were male. 76.8% of patients received the Pfizer-BioNTech vaccine, and 23.2% received the Moderna vaccine. 88.5% developed symptoms after the second dose. Patients were admitted to the hospital a median of three days post-vaccination. All the patients had chest pain and elevated troponin. The myocarditis was confirmed on cardiac MRI in 87% of the patients. Most of the patients had late gadolinium enhancement on MRI. The median length of stay was four days. All the reported patients recovered and were discharged. Conclusion: Post-mRNA vaccination myocarditis is seen predominantly in young males within a few days after their second dose of vaccination. The pathophysiology of myocarditis is not well known. The prognosis is good as all the reported patients recovered. The presence of late gadolinium enhancement on cardiac MRI indicated myocardial necrosis/fibrosis and further studies are needed to establish the long-term prognosis of the condition.

show abstract

Recurrence of Acute Myocarditis Temporally Associated with Receipt of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccine in a Male Adolescent

Cited by 63 publications

References 7 publications

Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID‐19 vaccine

Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID‐19 vaccine

Fulminant myocarditis in a patient with a lung adenocarcinoma after the third dose of modern COVID-19 vaccine. A case report and literature review

Clinical Presentation and Outcomes of Myocarditis Post mRNA Vaccination: A Meta-Analysis and Systematic Review

Contact Info

Product

Resources

About